SIM
AMAG

Stelliam Investment Management’s AMAG Pharmaceuticals AMAG Stock Holding History

Stelliam Investment Management’s Portfolio AMAG Stock Details AMAG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-572,500
Closed -$19.9M – 46
2016
Q4 		$19.9M Sell
572,500
-555,000
-49% -$16.6M 0.66% 40
2016
Q3 		$27.6M Buy
1,127,500
+32,500
+3% +$812K 0.92% 37
2016
Q2 		$26.2M Sell
1,095,000
-375,000
-26% -$8.6M 0.91% 39
2016
Q1 		$34.4M Buy
1,470,000
+785,000
+115% +$18.6M 1.06% 35
2015
Q4 		$20.7M Buy
+685,000
New +$22.1M 0.62% 42

Other funds holding AMAG

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
NI
Numeric Investors Boston, Massachusetts $13.7B AUM 28.88% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Stelliam Investment Management's AMAG Position: Q1 2017 in Review

Stelliam Investment Management sold out of AMAG Pharmaceuticals (AMAG) in Q1 2017, closing a stake of 572,500 shares — an estimated $19.9M sold.

Stelliam Investment Management first reported a position in AMAG in Q4 2015 and held it in 5 quarters. The position peaked at $34.4M in Q1 2016. 185 funds tracked by Wall St. Rank hold AMAG as of Q1 2017.

  • Stelliam Investment Management reported no remaining AMAG Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Stelliam Investment Management sold 572,500 AMAG Pharmaceuticals shares in Q1 2017, an estimated $19.9M.
  • Stelliam Investment Management first reported a position in AMAG Pharmaceuticals in Q4 2015 and held it in 5 quarters.
  • Stelliam Investment Management's AMAG Pharmaceuticals position peaked at $34.4M in Q1 2016.
  • 185 funds tracked by Wall St. Rank held AMAG Pharmaceuticals as of Q1 2017.

Based on Stelliam Investment Management's 13F filing for Q1 2017, filed 15 May 2017.